HC Wainwright Boosts Price Target on CymaBay Therapeutics Inc (CBAY)

Geronimo Vena
Luglio 18, 2017

Let's take an assessment at how Cymabay Therapeutics, Inc. They set an "outperform" rating and a $8.00 price target on the stock.

CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.07. The firm has "Neutral" rating given on Wednesday, January 4 by H.C. Wainwright.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and global trademark and copyright legislation.

Cymabay Therapeutics, Inc. (NASDAQ:CBAY)'s shares may have a significant upside to the consensus target of 8.79, but how has it been performing relative to the market?

Covering sell-side analysts have recently weighed in on shares of SeaDrill Limited (NYSE:SDRL). Finally, ValuEngine upgraded CymaBay Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, June 2nd.

Cymabay Therapeutics, Inc. has a consensus outperform rating from 5 Wall Street analysts, and the number of shares now sold short amount to at least 2.65% of shares outstanding. Finally, Piper Jaffray Companies boosted their target price on CymaBay Therapeutics from $5.00 to $6.50 and gave the stock an "overweight" rating in a research note on Friday, March 24th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company.

CymaBay Therapeutics (NASDAQ CBAY) opened at 5.56 on Monday.

The stock is now moving with a Positive distance from 200-Day Simple Moving Average of about 94.8% and has a pretty decent Year to Date (YTD) Performance of 245.66% which means the stock is constantly adding to its value from previous fiscal year end price. The company's market capitalization is $159.86 million. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $7.77.

Recent session action on shares of SeaDrill Limited (NYSE:SDRL) puts the stock on today's active list. Boxer Capital LLC purchased a new stake in CymaBay Therapeutics during the first quarter worth $3,342,000. Geode Capital Management LLC increased its position in shares of CymaBay Therapeutics by 71.4% in the first quarter. About 8.92M shares traded or 2049.19% up from the average. ClariVest Asset Management LLC purchased a new position in shares of CymaBay Therapeutics during the first quarter worth approximately $105,000. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company's stock worth $997,000 after buying an additional 114,549 shares during the period.

The company has 29.52 shares outstanding and 40.30% shares of the company were owned by institutional investors.

Shares of Cymabay Therapeutics, Inc. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases.

Altre relazioni OverNewsmagazine

Discuti questo articolo